Detalle Publicación


Treatment of steroid-refractory chronic graft-versus-host disease with imatinib: real-life experience of the Spanish group of hematopoietic transplantation (GETH)

Autores: Parra-Salinas, I. (Autor de correspondencia); Bermudez, A.; Lopez-Corral, L.; Lopez-Godino, O.; Moles-Poveda, P.; Martin, G.; Costilla-Barriga, L.; Ferra-Coll, C.; Marquez-Malaver, F.; Orti, G.; Zudaire-Ripa, M. T.; Rifón Roca, José Juan; Martinez, C.; Spanish Grp Hematopoietic Transpla
ISSN: 0902-0063
Volumen: 35
Número: 5
Páginas: e14255
Fecha de publicación: 2021
Treatment of steroid-refractory chronic graft-versus-host disease (cGVHD) is a challenge. Here, we describe a retrospective analysis of 66 patients with steroid-refractory cGVHD treated with imatinib (starting dose of 100 mg in 70% of patients; maximum dose of 100-200 mg in 74%). Most patients had multi-organ involvement (>= 2 organs, 83%), with the most affected being skin (85%), oral mucosa (55%), eyes (42%), and lungs (33%). The overall response rate was 41% (21 partial and three complete responses). The organ with the best response rate was the skin (46%), followed by gastrointestinal tract (43%), liver (41%), the oral mucosa (36%), eyes (29%), and lungs (18%). Imatinib led to steroid tapering in 17/38 patients. Twenty-five (38%) patients experienced imatinib-related adverse events, comprising extra-hematologic toxicity (n = 24, 36%) and hematologic toxicity (n = 6, 9%). No cases of grade 4-5 toxicity were reported. The main causes of imatinib discontinuation were treatment failure (52%) and toxicity (9%). After a median follow-up of 41 months, the 3-year overall survival was 81%, with no difference between imatinib responders and non-responders. These real-life results show that imatinib is safe and has moderate efficacy in patients with heavily pre-treated cutaneous sclerotic cGVHD; however, activity against lung cGVHD is very limited.